Karyopharm Therapeutics：计划于8月提交Selinexor联合Ruxolitinib治疗骨髓纤维化的sNDA申请按计划推进

美股速递08-13

Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1157957381?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-13 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157957381","market":"us","top_or_hot":-1,"title":"Karyopharm Therapeutics：计划于8月提交Selinexor联合Ruxolitinib治疗骨髓纤维化的sNDA申请按计划推进","media":"美股速递","content":"<p>Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics：计划于8月提交Selinexor联合Ruxolitinib治疗骨髓纤维化的sNDA申请按计划推进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics：计划于8月提交Selinexor联合Ruxolitinib治疗骨髓纤维化的sNDA申请按计划推进\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-13 19:35 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KPTI","symbol_name":"Karyopharm Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1157957381","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157957381","pubTimestamp":1786620958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KPTI":"Karyopharm Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Karyopharm Therapeutics: The sNDA application for Selinexor combined with Ruxolitinib for the treatment of myelofibrosis planned to be submitted in August is progressing as planned","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1},"content_text":"Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157957381","isCrawlerRequest":true}